News & Updates

Show Multimedia Only

Add-on bempedoic acid may benefit patients with statin intolerance

26 Sep 2021

Bempedoic acid may be a boon to patients with full statin intolerance, as its addition can lessen the need for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and serve as a less expensive alternative to established oral lipid-lowering medications, according to a study.

Add-on bempedoic acid may benefit patients with statin intolerance

26 Sep 2021

Educational intervention improves lung function, quality of life, inflammatory profile in asthmatics

26 Sep 2021

An educational intervention for proper inhaled corticosteroid use helps improve lung function, quality of life, and control of inflammation among asthma patients, a recent study has found.

Educational intervention improves lung function, quality of life, inflammatory profile in asthmatics

26 Sep 2021

Finerenone CV benefit extends to wide spectrum of CKD patients with T2D: FIGARO-DKD

25 Sep 2021 by

The large, phase III FIGARO-DKD trial strengthen the evidence on cardiovascular benefit (CV) of the nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone, in addition to its renal benefit, across a wide spectrum of patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).

Finerenone CV benefit extends to wide spectrum of CKD patients with T2D: FIGARO-DKD

25 Sep 2021

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Add-on bempedoic acid may benefit patients with statin intolerance

Add-on bempedoic acid may benefit patients with statin intolerance

Educational intervention improves lung function, quality of life, inflammatory profile in asthmatics

Educational intervention improves lung function, quality of life, inflammatory profile in asthmatics

Finerenone CV benefit extends to wide spectrum of CKD patients with T2D: FIGARO-DKD

Finerenone CV benefit extends to wide spectrum of CKD patients with T2D: FIGARO-DKD